Glycopyrronium Bromide Mercurypharm (Glycopyrronium Bromide)

Glycopyrronium Bromide Mercurypharm is indicated for several peri‑operative and respiratory applications.

• Reduction of salivary and respiratory secretions during surgery.
• Prevention of intra‑operative bradycardia.
• Adjunct therapy to reduce airway secretions in patients with chronic obstructive pulmonary disease (COPD).
• Facilitation of endotracheal intubation by decreasing oral and pharyngeal secretions.
• Management of excessive secretions in patients undergoing diagnostic or therapeutic procedures involving the airway.

The safety profile of Glycopyrronium Bromide Mercurypharm includes both frequent and less common adverse events.

Common

• Dry mouth (xerostomia).
• Reduced sweating (anhidrosis).
• Transient increase in heart rate.

Serious

• Severe tachycardia or arrhythmias.
• Marked hypotension.
• Allergic reactions such as rash, itching, or anaphylaxis.

When prescribing Glycopyrronium Bromide Mercurypharm, clinicians should consider several precautionary measures to ensure patient safety.

• Use cautiously in patients with cardiovascular disease, especially those prone to tachyarrhythmias.
• Assess renal and hepatic function, as impaired clearance may increase drug exposure.
• Avoid in individuals with known hypersensitivity to glycopyrronium or related anticholinergics.
• Monitor for signs of urinary retention, particularly in patients with prostate enlargement.
• Use with care in pregnant or breastfeeding women, as safety data are limited.
• Consider dose adjustment in elderly patients due to increased sensitivity to anticholinergic effects.

Glycopyrronium Bromide Mercurypharm can interact with other medications, influencing its efficacy or safety.

Avoid

• Concurrent use with other anticholinergic agents (e.g., atropine, scopolamine) may amplify anticholinergic side effects.
• Combination with beta‑adrenergic agonists may increase heart rate excessively.

Use with caution

• Concurrent administration of anesthetic agents that depress cardiac function (e.g., propofol) may require monitoring.
• Use with drugs that affect renal excretion (e.g., diuretics) may alter plasma levels.
• Co‑administration with medications that prolong QT interval should be monitored.